OpenURL Connection Search

Select item for more details and to access through your institution.

Histone H4 lysine 20 monomethylation promotes transcriptional repression by L3MBTL1.
Published in:
Oncogene, 2008, v. 27, n. 31, p. 4293, doi. 10.1038/onc.2008.67
By:
- Kalakonda, N;
- Fischle, W;
- Boccuni, P;
- Gurvich, N;
- Hoya-Arias, R;
- Zhao, X;
- Miyata, Y;
- MacGrogan, D;
- Zhang, J;
- Sims, J K;
- Rice, J C;
- Nimer, S D
Publication type:
Article
Gene expression in arsenic trioxide-resistant multiple myeloma.
Published in:
European Journal of Haematology, 2003, v. 70, n. 4, p. 265, doi. 10.1034/j.1600-0609.2003.01045.x
By:
- Comenzo, R.;
- Kalakonda, N.;
- Zhou, P.
Publication type:
Article
Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial.
Published in:
Bone Marrow Transplantation, 2005, v. 35, n. 5, p. 441, doi. 10.1038/sj.bmt.1704779
By:
- Gupta, S.;
- Zhou, P.;
- Hassoun, H.;
- Kewalramani, T.;
- Reich, L.;
- Costello, S.;
- Drake, L.;
- Klimek, V.;
- Dhodapkar, M.;
- Teruya-Feldstein, J.;
- Hedvat, C.;
- Kalakonda, N.;
- Fleisher, M.;
- Filippa, D.;
- Qin, J.;
- Nimer, S. D.;
- Comenzo, R. L.
Publication type:
Article
Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England.
Published in:
2022
By:
- Hounsome, L.;
- Eyre, T. A.;
- Ireland, R.;
- Hodson, A.;
- Walewska, R.;
- Ardeshna, K.;
- Chaganti, S.;
- McKay, P.;
- Davies, A.;
- Fox, C. P.;
- Kalakonda, N.;
- Fields, P. A.
Publication type:
journal article
CREATION OF ISOGENIC CELL LINE MODELS OF 17P DELETION TO STUDY CLONAL EVOLUTION AND MECHANISMS OF THERAPY RESISTANCE IN CLL AND DLBCL.
Published in:
Hematological Oncology, 2023, v. 41, p. 798, doi. 10.1002/hon.3165_647
By:
- van Kampen, F. L.;
- Glenn, M.;
- Pettitt, A.;
- Kalakonda, N.;
- Slupsky, J.
Publication type:
Article
Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L‐MIND study.
Published in:
Hematological Oncology, 2023, v. 41, p. 437, doi. 10.1002/hon.3164_323
By:
- Duell, J.;
- Abrisqueta, P.;
- Andre, M.;
- Augustin, M.;
- Gaidano, G.;
- Barca, E. G.;
- Jurczak, W.;
- Kalakonda, N.;
- Liberati, A. M.;
- Maddocks, K. J.;
- Menne, T.;
- Nagy, Z.;
- Tournilhac, O.;
- Bakuli, A.;
- Amin, A.;
- Gurbanov, K.;
- Salles, G.
Publication type:
Article
EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON‐1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC.
Published in:
Hematological Oncology, 2019, v. 37, p. 290, doi. 10.1002/hon.99_2630
By:
- Radford, J.;
- Connors, J.M.;
- Younes, A.;
- Gallamini, A.;
- Ansell, S.M.;
- Kim, W.S.;
- Cheong, J.;
- Flinn, I.;
- Kalakonda, N.;
- Kaminski, M.;
- Pettengell, R.;
- Onsum, M.;
- Josephson, N.;
- Kuroda, S.;
- Liu, R.;
- Miao, H.;
- Gautam, A.;
- Trepicchio, W.L.;
- Sureda, A.
Publication type:
Article
SAFETY AND EFFICACY OF THE PD‐L1 INHIBITOR DURVALUMAB WITH R‐CHOP OR R<sup>2</sup>‐CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK DLBCL.
Published in:
Hematological Oncology, 2019, v. 37, p. 132, doi. 10.1002/hon.93_2629
By:
- Nowakowski, G.;
- Willenbacher, W.;
- Greil, R.;
- Larsen, T.S.;
- Patel, K.;
- Jäger, U.;
- Manges, R.F.;
- Trümper, L.;
- Haioun, C.;
- Everaus, H.;
- Kalakonda, N.;
- Knoble, J.;
- Nully Brown, P.;
- Jørgensen, J.M.;
- Cunningham, D.;
- Domper Rubio, N.;
- Casadebaig, M.;
- Manzke, O.;
- Munoz, J.
Publication type:
Article
NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET‐GUIDED, RESPONSE‐ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED‐STAGE, HIGH‐TUMOUR‐BURDEN FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 67, doi. 10.1002/hon.35_2629
By:
- Pettitt, A.R.;
- Barrington, S.;
- Kalakonda, N.;
- Khan, U.T.;
- Jackson, R.;
- Carruthers, S.;
- Oates, M.;
- Lin, K.;
- Ardeshna, K.;
- Eyre, T.;
- Fox, C.P.;
- Kennedy, B.;
- Linton, K.;
- Malladi, R.;
- Menne, T.;
- Okosun, J.;
- Paneesha, S.;
- Rule, S.;
- Johnston, A.;
- Trotman, J.
Publication type:
Article
BRIEF CO‐ADMINISTRATION OF IDELALISIB MAY IMPROVE THE LONG‐TERM EFFICACY OF FRONTLINE CHEMOIMMUNOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKAEMIA: 3‐YEAR FOLLOW‐UP FROM THE RIALTO TRIAL.
Published in:
Hematological Oncology, 2019, v. 37, p. 217, doi. 10.1002/hon.32_2630
By:
- Pettitt, A.;
- Kalakonda, N.;
- Cicconi, S.;
- Murphy, C.;
- Menon, G.;
- Coupland, S.E.;
- Oates, M.;
- Lin, K.;
- Pocock, C.;
- Jenkins, S.;
- Schuh, A.;
- Wandroo, F.;
- Rassam, S.;
- Duncombe, A.S.;
- Cervi, P.;
- Paneesha, S.;
- Aldouri, M.;
- Fox, C.;
- Knechtli, C.;
- Hamblin, M.
Publication type:
Article
A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL).
Published in:
Hematological Oncology, 2019, v. 37, p. 62, doi. 10.1002/hon.31_2629
By:
- Kalakonda, N.;
- Cavallo, F.;
- Follows, G.;
- Goy, A.;
- Vermaat, J.;
- Casasnovas, O.;
- Lavee, O.;
- Maerevoet, M.;
- Zijlstra, J.;
- Bakshi, S.;
- Bouabdallah, R.;
- Choquet, S.;
- Gurion, R.;
- Hill, B.;
- Jaeger, U.;
- Sancho, J.;
- Schuster, M.;
- Thieblemont, C.;
- De la Cruz, F.;
- Egyed, M.
Publication type:
Article
POTENTIAL THERAPEUTIC ADVANTAGE FOR DUVELISIB IN MANTLE CELL LYMPHOMA: PI3Kδ AND OVEREXPRESSED PI3Kγ IN LYMPHOMA CELLS HAVE SPECIALIZED FUNCTIONAL ROLES.
Published in:
Hematological Oncology, 2019, v. 37, p. 511, doi. 10.1002/hon.194_2631
By:
- Till, K.J.;
- Gallardo Zapata, J.;
- Marks, T.;
- Weaver, D.T.;
- Pachter, J.A.;
- Abdullah, M.;
- Kalakonda, N.;
- Pettitt, A.R.;
- Slupsky, J.R.
Publication type:
Article
PRIMARY ANALYSIS RESULTS OF THE SINGLE‐ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (L‐MIND).
Published in:
Hematological Oncology, 2019, v. 37, p. 173, doi. 10.1002/hon.130_2629
By:
- Salles, G.;
- Duell, J.;
- González Barca, E.;
- Jurczak, W.;
- Liberati, A.M.;
- Nagy, Z.;
- Obr, A.;
- Gaidano, G.;
- Andre, M.;
- Kalakonda, N.;
- Dreyling, M.;
- Zinzani, P.L.;
- Dirnberger‐Hertweck, M.;
- Weirather, J.;
- Ambarkhane, S.;
- Maddocks, K.
Publication type:
Article
EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON‐1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC.
Published in:
Hematological Oncology, 2019, v. 37, p. 290, doi. 10.1002/hon.99_2630
By:
- Radford, J.;
- Connors, J.M.;
- Younes, A.;
- Gallamini, A.;
- Ansell, S.M.;
- Kim, W.S.;
- Cheong, J.;
- Flinn, I.;
- Kalakonda, N.;
- Kaminski, M.;
- Pettengell, R.;
- Onsum, M.;
- Josephson, N.;
- Kuroda, S.;
- Liu, R.;
- Miao, H.;
- Gautam, A.;
- Trepicchio, W.L.;
- Sureda, A.
Publication type:
Article
SAFETY AND EFFICACY OF THE PD‐L1 INHIBITOR DURVALUMAB WITH R‐CHOP OR R<sup>2</sup>‐CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK DLBCL.
Published in:
Hematological Oncology, 2019, v. 37, p. 132, doi. 10.1002/hon.93_2629
By:
- Nowakowski, G.;
- Willenbacher, W.;
- Greil, R.;
- Larsen, T.S.;
- Patel, K.;
- Jäger, U.;
- Manges, R.F.;
- Trümper, L.;
- Haioun, C.;
- Everaus, H.;
- Kalakonda, N.;
- Knoble, J.;
- Nully Brown, P.;
- Jørgensen, J.M.;
- Cunningham, D.;
- Domper Rubio, N.;
- Casadebaig, M.;
- Manzke, O.;
- Munoz, J.
Publication type:
Article
NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET‐GUIDED, RESPONSE‐ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED‐STAGE, HIGH‐TUMOUR‐BURDEN FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 67, doi. 10.1002/hon.35_2629
By:
- Pettitt, A.R.;
- Barrington, S.;
- Kalakonda, N.;
- Khan, U.T.;
- Jackson, R.;
- Carruthers, S.;
- Oates, M.;
- Lin, K.;
- Ardeshna, K.;
- Eyre, T.;
- Fox, C.P.;
- Kennedy, B.;
- Linton, K.;
- Malladi, R.;
- Menne, T.;
- Okosun, J.;
- Paneesha, S.;
- Rule, S.;
- Johnston, A.;
- Trotman, J.
Publication type:
Article
BRIEF CO‐ADMINISTRATION OF IDELALISIB MAY IMPROVE THE LONG‐TERM EFFICACY OF FRONTLINE CHEMOIMMUNOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKAEMIA: 3‐YEAR FOLLOW‐UP FROM THE RIALTO TRIAL.
Published in:
Hematological Oncology, 2019, v. 37, p. 217, doi. 10.1002/hon.32_2630
By:
- Pettitt, A.;
- Kalakonda, N.;
- Cicconi, S.;
- Murphy, C.;
- Menon, G.;
- Coupland, S.E.;
- Oates, M.;
- Lin, K.;
- Pocock, C.;
- Jenkins, S.;
- Schuh, A.;
- Wandroo, F.;
- Rassam, S.;
- Duncombe, A.S.;
- Cervi, P.;
- Paneesha, S.;
- Aldouri, M.;
- Fox, C.;
- Knechtli, C.;
- Hamblin, M.
Publication type:
Article
A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL).
Published in:
Hematological Oncology, 2019, v. 37, p. 62, doi. 10.1002/hon.31_2629
By:
- Kalakonda, N.;
- Cavallo, F.;
- Follows, G.;
- Goy, A.;
- Vermaat, J.;
- Casasnovas, O.;
- Lavee, O.;
- Maerevoet, M.;
- Zijlstra, J.;
- Bakshi, S.;
- Bouabdallah, R.;
- Choquet, S.;
- Gurion, R.;
- Hill, B.;
- Jaeger, U.;
- Sancho, J.;
- Schuster, M.;
- Thieblemont, C.;
- De la Cruz, F.;
- Egyed, M.
Publication type:
Article
POTENTIAL THERAPEUTIC ADVANTAGE FOR DUVELISIB IN MANTLE CELL LYMPHOMA: PI3Kδ AND OVEREXPRESSED PI3Kγ IN LYMPHOMA CELLS HAVE SPECIALIZED FUNCTIONAL ROLES.
Published in:
Hematological Oncology, 2019, v. 37, p. 511, doi. 10.1002/hon.194_2631
By:
- Till, K.J.;
- Gallardo Zapata, J.;
- Marks, T.;
- Weaver, D.T.;
- Pachter, J.A.;
- Abdullah, M.;
- Kalakonda, N.;
- Pettitt, A.R.;
- Slupsky, J.R.
Publication type:
Article
PRIMARY ANALYSIS RESULTS OF THE SINGLE‐ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (L‐MIND).
Published in:
Hematological Oncology, 2019, v. 37, p. 173, doi. 10.1002/hon.130_2629
By:
- Salles, G.;
- Duell, J.;
- González Barca, E.;
- Jurczak, W.;
- Liberati, A.M.;
- Nagy, Z.;
- Obr, A.;
- Gaidano, G.;
- Andre, M.;
- Kalakonda, N.;
- Dreyling, M.;
- Zinzani, P.L.;
- Dirnberger‐Hertweck, M.;
- Weirather, J.;
- Ambarkhane, S.;
- Maddocks, K.
Publication type:
Article
EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL.
Published in:
Hematological Oncology, 2017, v. 35, p. 88, doi. 10.1002/hon.2437_77
By:
- Pettitt, A.R.;
- Kalakonda, N.;
- Polydoros, F.;
- Bickerstaff, M.;
- Menon, G.;
- Coupland, S.E.;
- Oates, M.;
- Lin, K.;
- Pocock, C.;
- Jenkins, S.;
- Schuh, A.;
- Wandroo, F.;
- Rassam, S.;
- Duncombe, A.S.;
- Jenner, M.;
- Cervi, P.;
- Paneesha, S.;
- Aldouri, M.;
- Fox, C.P.;
- Knechtli, C.
Publication type:
Article
PHASE II STUDY OF DURVALUMAB (ANTI-PD-L1) COMBINED WITH EITHER R-CHOP OR LENALIDOMIDE AND R-CHOP IN PREVIOUSLY UNTREATED, HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA.
Published in:
Hematological Oncology, 2017, v. 35, p. 419, doi. 10.1002/hon.2440_1
By:
- Jaeger, U.;
- Kalakonda, N.;
- Everaus, H.;
- Fustier, P.;
- Jaeger, J.;
- Manzke, O.;
- Nowakowski, G.S.
Publication type:
Article
L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) - A SINGLE-ARM PHASE II STUDY.
Published in:
Hematological Oncology, 2017, v. 35, p. 51, doi. 10.1002/hon.2437_35
By:
- Salles, G.;
- González Barca, E.;
- Jurczak, W.;
- Liberati, A.M.;
- Duell, J.;
- Nagy, Z.;
- Papajík, T.;
- Andre, M.;
- Kalakonda, N.;
- Dreyling, M.;
- Zinzani, P.L.;
- Ambarkhane, S.;
- Weirather, J.;
- Maddocks, K.
Publication type:
Article
research paper Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association.
Published in:
British Journal of Haematology, 2004, v. 124, n. 3, p. 309, doi. 10.1046/j.1365-2141.2003.04779.x
By:
- Cohen, A.D.;
- Zhou, P.;
- Xiao, Q.;
- Fleisher, M.;
- kalakonda, N.;
- Akhurst, T.;
- Chitale, D.A.;
- Moscowitz, C.;
- Dhodapkar, M.V.;
- Teruya-Feldstein, J.;
- Filippa, D.;
- Comenzo, R.L.
Publication type:
Article

Found: 24